Norroy wins China clearance for Phase III 177Lu-NYM032 prostate cancer trial
AI Summary- Norroy Bioscience received NMPA clearance to initiate a Phase III trial of 177Lu-NYM032 in China.
- The study will evaluate efficacy and safety in PSMA-positive metastatic castration-resistant prostate cancer patients.
- 68Ga-NYM032 was previously dosed in a first Phase III patient, and the pair has U.S. FDA IND clearance.